Acetazolamide for Treatment Resistant Schizophrenia

Description

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

Conditions

Schizophrenia, Schizo Affective Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia

Acetazolamide for Treatment Resistant Schizophrenia

Condition
Schizophrenia
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

University of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15213

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Written informed consent.
  • * Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
  • * PANSS total score \> 60 and Score \> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
  • * Stable dose of antipsychotic drug (APD) for \> 1 month, continued throughout the study.
  • * Not participating in another randomized controlled clinical trial (RCT).
  • * Substance abuse in the past month/dependence past 6 months, (except nicotine).
  • * History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
  • * Pregnancy.
  • * Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
  • * Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
  • * Intellectual disability as defined in DSM 5.

Ages Eligible for Study

18 Years to 55 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Vishwajit Nimgaonkar, MD PhD,

Vishwajit L Nimgaonkar, M.D., Ph.D., PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

2025-06-30